New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 9, 2014
08:08 EDTACSTAcasti Pharma completes Phase II TRIFECTA, Pharmacokinetic trials
Acasti Pharma announces the completion of two trials, the Phase II double-blind, placebo-controlled, or TRIFECTA, study and the Pharmacokinetic trial. The primary objective of the TRIFECTA trial is to evaluate the safety and efficacy of CaPre in reducing triglyceride levels in patients with mild to severe hypertriglyceridemia. Given that the stopping threshold had been met, the data review committee members recommended that there was sufficient evidence of a treatment effect that warranted the termination of the study. The corporation intends to unblind the study and top-line results are expected by the end of September, with full data coming out in the following quarter. Acasti's Pharmacokinetic trial is designed to evaluate blood profiles and bioavailability in healthy human volunteers taking single and multiple doses of Capre. Top-line results are expected to be available by the end of September, with full data coming out in the following quarter.
News For ACST From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 25, 2015
07:37 EDTACSTAcasti Pharma granted patent in China
Subscribe for More Information
March 23, 2015
19:10 EDTACSTNeptune, Acasti announce USPTO decision that triggers royalty payments
Neptune Technologies & Bioressources (NEPT) and Acasti Pharma (ACST) announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office, or USPTO, issued a favorable decision, confirming the validity of certain claims in Neptune's '351 patent and triggering royalty payments to Neptune. "This is a significant milestone that triggers the payment of ongoing royalties to Neptune by Aker and Enzymotec, based on their sales of licensed krill oil products in the US," said Neptuine CEO Jim Hamilton.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use